Oxford-AstraZeneca Covid-19 vaccine can be 90% effective
British-Swedish drugmaker AstraZeneca said on Monday its covid vaccine for the novel coronavirus, developed along with the University of Oxford, could be around 90% effective under one dosing regimen.
The British-Swedish drugmaker’s preliminary trial results mark a fresh breakthrough in the fight against a pandemic that has killed nearly 1.4 million people and roiled the global economy.
AstraZeneca’s covid vaccine efficacy and safety confirm that it will be highly effective against COVID-19 and will have an immediate impact on this public health emergency.
Furthermore, the vaccine’s simple supply chain and the drug makers no-profit pledge and commitment to broad, equitable and timely access means it will be affordable and globally available, supplying hundreds of millions of doses on approval.
Oxford and AstraZeneca are waiting for the results of phase III trials of their coronavirus vaccine candidate ‘AZD1222’ on thousands of people around the world to show whether their vaccine is safe and effective.
AstraZeneca is “making rapid progress in manufacturing with a capacity of up to 3 billion doses of the vaccine in 2021 on a rolling basis, pending regulatory approval. The vaccine can be stored, transported and handled at normal refrigerated conditions (2-8 degrees Celsius/ 36-46 degrees Fahrenheit) for at least six months and administered within existing healthcare settings.
Last week, Pfizer and Moderna had reported promising results from vaccine trials. The coronavirus vaccine developed by Pfizer has shown 95% efficacy in the late-stage trial
This document is meant for the recipient only for use as intended and not for circulation. This document should not be reproduced or copied or made available to others. The information contained herein is from the public domain or sources believed to be reliable. While reasonable care has been taken to ensure that information given is at the time believed to be fair and correct and opinions based thereupon are reasonable, due to the very nature of research it cannot be warranted or represented that it is accurate or complete and it should not be relied upon as such. Also above note is not a recommendation to Buy or SELL and is only a view based on facts and figures and we will be in no way responsible for any losses incurred by anyone who uses this information to either trade or invests securities mentioned herein.